1. Scrip
  2. >>Conferences
  3. >>J.P. Morgan

Servier Plots Route Into Neurology Through BD

 
• By Jessica Merrill

CEO David Lee, who oversees Servier’s US business, and chief scientific officer Claude Bertrand talked to Scrip at J.P. Morgan about expanding into neurology through business development.

(Shutterstock)

Servier Pharmaceuticals CEO David Lee, who oversees the French company’s US business, and chief scientific officer Claude Bertrand were at the J.P. Morgan Healthcare Conference with a purpose: to find new neurology drug candidates to bring in-house.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from J.P. Morgan

BMS Enters A Catalyst-Rich Era Full Of Both LOEs And New Launches

 
• By Mandy Jackson

Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.

Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D

 
• By Mandy Jackson

Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.

Momentum In Women’s Health, But Big Obstacles Too

 
• By Jessica Merrill

Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.

Amgen Building On Repatha Experience As It Grows In Cardiovascular, Obesity

 
• By Mandy Jackson

Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.

More from Neurological

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By Joseph Haas

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.

Cassava At Crossroads As Simufilam Finally Exits, Stage Left

 
• By Alexandra Shimmings

The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.

Axsome Scores In ADHD, But Differentiation In Generic-Heavy Market Unclear

 
• By Alaric DeArment

The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.